Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study

CHIUN-SHENG HUANGYang, YoungsenYoungsenYangKwong, AvaAvaKwongChen, Shin-ChehShin-ChehChenTseng, Ling-MingLing-MingTsengLiu, Mei-ChingMei-ChingLiuShen, KunweiKunweiShenWang, ShusenShusenWangNg, Ting-YingTing-YingNgFeng, YiYiFengSun, GuofangGuofangSunYan, Iris RenfeiIris RenfeiYanShao, ZhiminZhiminShao2021-06-042021-06-042021-04-1501676806https://scholars.lib.ntu.edu.tw/handle/123456789/565119In the KATHERINE study (NCT01772472), patients with HER2-positive early breast cancer (EBC) and residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy who were treated with adjuvant trastuzumab emtansine (T-DM1) had a 50% reduction in the risk of an invasive disease-free survival (IDFS) event compared to patients treated with adjuvant trastuzumab. In metastatic disease, T-DM1 has resulted in higher rates of thrombocytopenia in Asian versus non-Asian patients. Here, we report safety and efficacy in Chinese patients from KATHERINE.enChinese; Early breast cancer; HER2-positive; Invasive disease-free survival (IDFS); Thrombocytopenia; Trastuzumab emtansine (T-DM1)[SDGs]SDG3afatinib; alanine aminotransferase; aspartate aminotransferase; bilirubin; dacomitinib; lapatinib; neratinib; pertuzumab; taxane derivative; trastuzumab; trastuzumab emtansine; antineoplastic agent; epidermal growth factor receptor 2; maytansine; trastuzuTrastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE studyjournal article10.1007/s10549-021-06166-y338603892-s2.0-85104745938https://api.elsevier.com/content/abstract/scopus_id/85104745938